In:
The Journal of Pathology, Wiley, Vol. 242, No. 1 ( 2017-05), p. 73-89
Kurzfassung:
Bone metastasis affects 〉 70% of patients with advanced breast cancer. However, the molecular mechanisms underlying this process remain unclear. On the basis of analysis of clinical datasets, and in vitro and in vivo experiments, we report that the ZNF217 oncogene is a crucial mediator and indicator of bone metastasis. Patients with high ZNF217 mRNA expression levels in primary breast tumours had a higher risk of developing bone metastases. MDA‐MB ‐231 breast cancer cells stably transfected with ZNF217 ( MDA‐MB ‐231‐ ZNF217 ) showed the dysregulated expression of a set of genes with bone‐homing and metastasis characteristics, which overlapped with two previously described ‘osteolytic bone metastasis’ gene signatures, while also highlighting the bone morphogenetic protein ( BMP ) pathway. The latter was activated in MDA‐MB ‐231‐ ZNF217 cells, and its silencing by inhibitors (Noggin and LDN ‐193189) was sufficient to rescue ZNF217 ‐dependent cell migration, invasion or chemotaxis towards the bone environment. Finally, by using non‐invasive multimodal in vivo imaging, we found that ZNF217 increases the metastatic growth rate in the bone and accelerates the development of severe osteolytic lesions. Altogether, the findings of this study highlight ZNF217 as an indicator of the emergence of breast cancer bone metastasis; future therapies targeting ZNF217 and/or the BMP signalling pathway may be beneficial by preventing the development of bone metastases. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Materialart:
Online-Ressource
ISSN:
0022-3417
,
1096-9896
DOI:
10.1002/path.2017.242.issue-1
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
1475280-3
